James C. Clemmer Purchases 5,000 Shares of AngioDynamics, Inc. (ANGO) Stock
AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer purchased 5,000 shares of the business’s stock in a transaction on Friday, July 21st. The stock was acquired at an average cost of $15.79 per share, with a total value of $78,950.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
AngioDynamics, Inc. (NASDAQ:ANGO) traded down 0.63% during mid-day trading on Friday, reaching $15.65. 325,430 shares of the company’s stock were exchanged. The stock’s market cap is $575.61 million. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.18. The stock has a 50-day moving average price of $15.88 and a 200-day moving average price of $16.23.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The company’s revenue was down 7.0% on a year-over-year basis. During the same period last year, the company earned $0.19 earnings per share. On average, analysts forecast that AngioDynamics, Inc. will post $0.67 earnings per share for the current year.
ANGO has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, March 29th. Barclays PLC cut their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Wednesday. Canaccord Genuity reissued a “hold” rating and issued a $17.50 price target on shares of AngioDynamics in a report on Thursday, March 30th. Cantor Fitzgerald upped their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Finally, Craig Hallum set a $20.00 price target on shares of AngioDynamics and gave the company a “buy” rating in a report on Saturday, April 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. AngioDynamics currently has a consensus rating of “Hold” and a consensus price target of $18.50.
A number of hedge funds have recently made changes to their positions in ANGO. Norges Bank purchased a new stake in shares of AngioDynamics during the fourth quarter worth approximately $2,699,000. Bowling Portfolio Management LLC purchased a new stake in shares of AngioDynamics during the first quarter worth approximately $653,000. FMR LLC raised its stake in shares of AngioDynamics by 1.8% in the fourth quarter. FMR LLC now owns 1,140,000 shares of the medical instruments supplier’s stock worth $19,232,000 after buying an additional 20,000 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in shares of AngioDynamics by 6.6% in the first quarter. Great West Life Assurance Co. Can now owns 43,489 shares of the medical instruments supplier’s stock worth $754,000 after buying an additional 2,702 shares during the last quarter. Finally, Comerica Bank raised its stake in shares of AngioDynamics by 5.8% in the first quarter. Comerica Bank now owns 35,175 shares of the medical instruments supplier’s stock worth $537,000 after buying an additional 1,932 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.